Stockman Wealth Management Inc. Decreases Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Stockman Wealth Management Inc. trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 7.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,857 shares of the biopharmaceutical company’s stock after selling 318 shares during the quarter. Stockman Wealth Management Inc.’s holdings in Bristol-Myers Squibb were worth $218,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. AMF Tjanstepension AB increased its holdings in shares of Bristol-Myers Squibb by 6.9% during the third quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock valued at $31,618,000 after acquiring an additional 39,419 shares in the last quarter. Atomi Financial Group Inc. acquired a new position in shares of Bristol-Myers Squibb during the third quarter valued at about $371,000. Wedmont Private Capital increased its holdings in Bristol-Myers Squibb by 14.1% in the 3rd quarter. Wedmont Private Capital now owns 8,095 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 999 shares during the period. Perpetual Ltd raised its position in Bristol-Myers Squibb by 5.4% during the 3rd quarter. Perpetual Ltd now owns 24,209 shares of the biopharmaceutical company’s stock worth $1,253,000 after buying an additional 1,243 shares during the last quarter. Finally, Quotient Wealth Partners LLC purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at approximately $226,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of recent research reports. Sanford C. Bernstein initiated coverage on shares of Bristol-Myers Squibb in a research note on Thursday, October 17th. They set a “market perform” rating and a $56.00 target price on the stock. Morgan Stanley increased their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Friday. Finally, BMO Capital Markets increased their price objective on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $57.86.

Bristol-Myers Squibb Trading Down 0.8 %

Shares of BMY stock opened at $56.96 on Friday. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.10. The stock has a fifty day moving average of $57.56 and a two-hundred day moving average of $53.75. The firm has a market capitalization of $115.51 billion, a PE ratio of -12.89, a price-to-earnings-growth ratio of 2.13 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.81% and a negative net margin of 18.53%. As a group, research analysts expect that Bristol-Myers Squibb will post 6.75 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were given a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.35%. Bristol-Myers Squibb’s payout ratio is -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.